Pemvidutide Phase 2b shows fibrosis regression in MASH
Altimmune's dual GLP-1/glucagon agonist hit fibrosis regression and non-invasive marker endpoints in the 212-patient IMPACT trial, presented at EASL 2026.
May 28, 2026 · 3 min read
Altimmune (Nasdaq: ALT) presented Phase 2b data on pemvidutide — a dual GLP-1/glucagon receptor agonist peptide — at the European Association for the Study of the Liver (EASL) Congress 2026 in Barcelona on May 27. The IMPACT trial enrolled 212 patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stages F2 or F3, and reported fibrosis regression rates of 68.6% on the 1.2 mg weekly dose versus 29.6% on placebo at 24 weeks. The company plans to launch a Phase 3 trial (PERFORMA) in the second half of 2026.
This is a significant data drop in the rapidly evolving liver-targeting peptide space — and it has indirect implications for the strength-peptide community via Tesamorelin's increasingly recognized role in liver fat reduction.
What happened
The IMPACT trial randomized 212 MASH patients with biopsy-confirmed F2 or F3 fibrosis to weekly subcutaneous pemvidutide at 1.2 mg, 1.8 mg, or placebo over 48 weeks, with primary efficacy assessed at 24 weeks. Headline results presented at EASL:
-
Fibrosis regression (≥1 stage, via AI-based digital pathology qFibrosis):
- Pemvidutide 1.2 mg: 68.6% (p less than 0.001 vs placebo)
- Pemvidutide 1.8 mg: 54.5% (p=0.002 vs placebo)
- Placebo: 29.6%
-
Concurrent improvement on non-invasive markers (>0.5 ELF reduction + >30% liver stiffness measurement reduction):
- Pemvidutide 1.2 mg: 37.8% (p=0.0002 vs placebo)
- Pemvidutide 1.8 mg: 22.7% (p=0.02 vs placebo)
- Placebo: 8.3%
Interestingly, the lower dose (1.2 mg) outperformed the higher dose (1.8 mg) on several endpoints — a finding that warrants investigation but isn't uncommon in dose-finding work for peptides with multiple mechanisms.
The Phase 3 trial, PERFORMA, is planned to launch in the second half of 2026.
Why it matters
Pemvidutide isn't a strength-peptide product, but the broader peptide-for-metabolic-disease story is relevant to anyone in the GLP-1 era. Three angles matter:
The MASH/MASLD space is becoming central to metabolic medicine. Liver fat is increasingly recognized as a key marker of metabolic health, distinct from BMI. Peptides that target liver fat directly (Tesamorelin in HIV-associated lipodystrophy, pemvidutide in MASH) are clinically significant.
Dual and triple agonist mechanisms are expanding. Pemvidutide adds glucagon agonism to GLP-1 agonism (the semaglutide mechanism). Retatrutide (see our Retatrutide TRIUMPH-1 coverage) adds GIP and glucagon. The "more receptors, more effect" thesis is being repeatedly validated.
The Tesamorelin connection. Tesamorelin (already FDA-approved for HIV-associated lipodystrophy) has documented effects on liver fat — see the recent Tesamorelin meta-analysis for the 5-RCT pooled data. Users with metabolic syndrome features and hepatic concerns may have Tesamorelin as the closer-to-hand peptide option while pemvidutide progresses through Phase 3.
For the broader strength-peptide context around metabolic health see insulin sensitivity in midlife with peptides and tesamorelin protocol.
What to watch
Several things over the next 12–18 months:
- PERFORMA Phase 3 initiation — H2 2026. Trial design and primary endpoints will signal Altimmune's regulatory strategy.
- Pemvidutide AUD/ALD development — the same molecule is being developed for alcohol use disorder and alcohol-associated liver disease. Multi-indication peptides are commercially more attractive.
- Competitive landscape — pemvidutide is one of several MASH-targeted peptides in late-stage development. The class will continue moving.
- Tesamorelin off-label use in liver fat — as MASH treatments accumulate, off-label use of approved peptides (Tesamorelin) for related indications may grow in concierge medicine.
Sources
Sources